PsychoGenics Announces Drug Discovery Agreement with Cephalon
News Nov 13, 2007
PsychoGenics Inc. has announced that it has entered into a drug discovery agreement with Cephalon, Inc. The agreement provides that Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies.
PsychoGenics and Cephalon aim to jointly identify drug candidates suitable for clinical development. If Cephalon undertakes further development of the clinical candidates, PsychoGenics will receive milestone payments as well as royalties. If PsychoGenics undertakes further development, it will make milestone and royalty payments to Cephalon.
Dr. Emer Leahy, President and CEO of PsychoGenics, said, "We are delighted to partner with Cephalon and look forward to a successful collaboration. We are confident that combining Cephalon’s and PsychoGenics’ complementary strengths and expertise will enable us to identify a new generation of treatments for neuropsychiatric disorders.”
PsychoGenics’ technologies combine its broad in vivo behavioral expertise together with recent developments in robotics, computer vision and bio/cheminformatics to evaluate drug candidates for potential therapeutic utility across the spectrum of neuropsychiatric disease indications.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019